Status:
UNKNOWN
Nutritional Therapy in Late-onset Pompe Disease
Lead Sponsor:
McMaster University
Conditions:
Pompe Disease
Muscle Loss
Eligibility:
All Genders
21-90 years
Phase:
PHASE2
Brief Summary
RATIONALE: Pompe disease (PD) is a recessive genetic disorder wherein the body cannot break down glycogen due to a mutation in the acid alpha glucosidase (GAA) gene, which encodes for acid alpha-gluco...
Detailed Description
DESIGN AND INTERVENTION: The present study is a 4-month randomized, double-blind, placebo-controlled clinical trial (RCT) with sampling pre and post intervention in late onset Pompe disease patients u...
Eligibility Criteria
Inclusion
- Genetically confirmed LOPD
- Have undergone enzyme replacement therapy for at least three months.
- Physically capable of doing rehabilitative exercise, respiratory muscle training, and the clinical tests described herein.
Exclusion
- Dairy protein allergy
- Renal disease (creatinine \> 140)
- Attempting pregnancy or currently pregnant
- Current supplementation
Key Trial Info
Start Date :
April 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2025
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT06130228
Start Date
April 1 2024
End Date
April 1 2025
Last Update
November 14 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.